Dergiler / Turkish Journal of Endocrinology and Metabolism / 2019 / Cilt: 23 - Sayı: 4

Therapeutic Plasmapheresis in Amiodarone-Induced Thyrotoxicosis Resistant to Medical Therapy

Medikal Tedaviye Dirençli Amiodaron ile İlişkili Tirotoksikozda Terapötik Plazmaferez Tedavisi

Sayfa
253–258
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In this case report, we discussed the potential option of TP treatment in the surgical preparation of a patient with Type 1 amiodarone-induced thyrotoxicosis resistant to antithyroid therapy.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Amiodarone treatment is associated with thyroid dysfunction resulting in life-threatening thyrotoxicosis.
📊
Temel Bulgular & Veri:Therapeutic plasmapheresis (TP) may thus be considered to ensure perioperative euthyroidism, prevent thyroid storm and decrease the risk in surgery.
💡
Sonuç & Katkı:In this case report, we discussed the potential option of TP treatment in the surgical preparation of a patient with Type 1 amiodarone-induced thyrotoxicosis resistant to antithyroid therapy.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Amiodarone treatment is associated with thyroid dysfunction resulting in life-threatening thyrotoxicosis. Thyroidectomy may be required if medication is contraindicated or thyroid dysfunction is resistant to the treatment. Therapeutic plasmapheresis (TP) may thus be considered to ensure perioperative euthyroidism, prevent thyroid storm and decrease the risk in surgery. In this case report, we discussed the potential option of TP treatment in the surgical preparation of a patient with Type 1 amiodarone-induced thyrotoxicosis resistant to antithyroid therapy.

Abstract

Amiodaron tedavisi tiroid disfonksiyonu ve hayatı tehdit eden tirotoksikoz ile ilişkilidir. Tıbbi olarak dirençli olgularda veya medikal tedavinin kontrendike olduğu durumlarda tiroidektomi gerekebilir. Perioperatif ötiroidizmi sağlamak, tiroid krizi ve cerrahi riskini azaltmak için terapötik plazmaferez (TP) düşünülebilir. Bu olgu sunumundai Tip 1 amiodaron ilişkili tirotoksikozu olan ancak antitiroid tedaviye dirençli olguda cerrahi hazırlıkta TP tedavisinin bir seçenek olabileceği tartışılmaktadır.

🔖

Bu Makaleye Atıf Yap

ŞAHİN, M., OĞUZ, A., TÜZÜN, D., ÜLGEN, C., ÇALKAYA, S., GÜNGÖR, Ö., YAZAR, F. M., GÜL, K. (2019). Therapeutic Plasmapheresis in Amiodarone-Induced Thyrotoxicosis Resistant to Medical Therapy. Turkish Journal of Endocrinology and Metabolism, Cilt: 23 - Sayı: 4, 253–258. https://ajindex.com/articles/370706

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Iervasi G, Clerico A, Bonini R, Manfredi C, Berti S, Ravani M, Palmieri C, Carpi A, Biagini A, Chopra IJ. Acute effects of amiodarone administration on thyroid function in patients with cardiac arrhythmia. J Clin Endocrinol Metab. 1997;82(1):275-80. [Crossref] [PubMed] 2. Rao RH, McCready VR, Spathis GS. Iodine kinetic studies during amiodarone treatment. J Clin Endocrinol Metab. 1986;62:563-8. [Crossref] [PubMed] 3. Harjai KJ. Effects of amiodarone on thyroid function. Vol. 126. Ann Intern Med. 2013;63. [Crossref] [PubMed] 4. Trip MD, Wiersinga W, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med. 1991;91:507-511. [Crossref] [PubMed] 5. Bartalena L, Brogioni S, Grasso L, Bogazzi F, Burelli A, Martino E. Treatment of amiodaroneinduced thyrotoxicosis, a difficult challenge: results of a prospective study. J Clin Endocrinol Metab. 1996;81:2930-2933. [Crossref] [PubMed] 6. Bartalena L, Grasso L, Brogioni S, Aghini-Lombardi F, Braverman LE, Martino E. Serum interleukin-6 in amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab. 1994;78:423-427. [Crossref] [PubMed] 7. Bartalena L, Bogazzi F, Chiovato L, Hubalewska-Dydejczyk A, Links TP, Vanderpump M. 2018 European Thyroid Association (ETA) guidelines for the management of amiodarone-associated thyroid dysfunction. Eur Thyroid J. 2018;7:55-66. [Crossref] [PubMed] [PMC] 8. Newnham HH, Topliss DJ, Le Grand BA, Chosich N, Harper RW, Stockıgt JR. Amiodarone‐induced hyperthyroidism: assessment of the predictive value of biochemical testing and response to combined therapy using propylthiouracil and potassium perchlorate. Aust N Z J Med. 1988;18:37-44. [Crossref] [PubMed] 9. Yiu KH, Jim MH, Siu CW, Lee CH, Yuen M, Mok M, Shea YF, Fan K, Tse HF, Chow WH. Amiodarone-induced thyrotoxicosis is a predictor of adverse cardiovascular outcome. J Clin Endocrinol Metab. 2009;94:109-114. [Crossref] [PubMed] 10.Tomisti L, Materazzi G, Bartalena L, Rossi G, Marchello A, Moretti M, De Napoli L, Mariotti R, Miccoli P, Martino E, Bogazzi F. Total thyroidectomy in patients with amiodarone-induced thyrotoxicosis and severe left ventricular systolic dysfunction. J Clin Endocrinol Metab. 2012;97:3515-3521. [Crossref] [PubMed] 11.Bartges JW. Therapeutic plasmapheresis. Vol. 12. Seminars in Veterinary Medicine and Surgery-Small Animal. Philadelphia, PA, USA: Elsevier; 1997;170-7. [Crossref] 12.Lukomskiĭ GI, Alekseeva ME, Ivanova NA, Kabanova GM, Tatsievskiĭ VA, S